【Abstract】 Objective We aimed to investigate how admission hyperglycemia and glycosylated hemoglobin A1c(HbA1c) affects clinical prognosis of nondiabetic patients after primary percutaneous coronary intervention for acute myocardial infarction (AMI). Methods We retrospectively analyzed 452 consecutive nondiabetic patients with AMI. All patients were treated with pPCI. Patients were divided into four groups according to the median values of admission glucose and HbA1c. Group A: AG＜120mg/dL＋HbA1c＜51%(n=113); Group B: AG＜120mg/dL＋HbA1c≥51%(n=114); Group C: AG≥120mg/dL＋HbA1c＜51%(n=108); Group D: AG≥120mg/dL＋HbA1c≥51%(n=117). The primary endpoint included a composite of allcause death and nonfatal MI. The four groups were compared with respect to baseline characteristics, clinical characteristics and other major adverse cardiovascular events (MACE). Results The primary endpoint occurred in 137% of the participants. Compared with other groups, incidence of nonfatal MI(68%), MACE(86%) and allcause mortality(157%) in the D group were higher than other groups (P＜005). The combination of elevated admission glucose and HbA1c were an independent predictor of the primary endpoint(HR, 265；95% CI：117658, P=002). Conclusion In patients with AMI undergoing pPCI, the patients with the combination of elevated admission glucose and HbA1c experienced a significantly higher incidence of nonfatal MI, MACE and allcause mortality, as an independent predictor of longterm clinical outcomes.